Unicycive Total Current Assets vs Common Stock Analysis
UNCY Stock | USD 0.55 0.02 3.77% |
Unicycive Therapeutics financial indicator trend analysis is much more than just breaking down Unicycive Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unicycive Therapeutics is a good investment. Please check the relationship between Unicycive Therapeutics Total Current Assets and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.
Total Current Assets vs Common Stock
Total Current Assets vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unicycive Therapeutics Total Current Assets account and Common Stock. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Unicycive Therapeutics' Total Current Assets and Common Stock is -0.26. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Common Stock in the same time period over historical financial statements of Unicycive Therapeutics, assuming nothing else is changed. The correlation between historical values of Unicycive Therapeutics' Total Current Assets and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Unicycive Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Current Assets i.e., Unicycive Therapeutics' Total Current Assets and Common Stock go up and down completely randomly.
Correlation Coefficient | -0.26 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Common Stock
Most indicators from Unicycive Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 12.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.4 M in 2024.
Unicycive Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Unicycive Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Unicycive Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Current Liabilities | 903K | 2.9M | 2.1M | 3.3M | 17.5M | 18.4M | |
Retained Earnings | (3.7M) | (5.9M) | (15.9M) | (34.0M) | (64.5M) | (61.3M) | |
Accounts Payable | 322K | 184K | 713K | 846K | 821K | 540.1K | |
Total Current Assets | 19K | 204K | 18.4M | 2.6M | 13.4M | 14.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.